Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure

Brian Bressler, MSc, MD1, Martin Williamson, PhD2, Bernie Sattin, PhD2, Fernando Camacho, PhD3, A. Hillary Steinhart, MSc, MD4,5

1University of British Columbia, Vancouver, British Columbia, Canada; 2Janssen Inc., Toronto, Ontario, Canada; 3Damos Inc., Toronto, Ontario, Canada; 4Division of Gastroenterology, Mount Sinai Hospital IBD Centre, Toronto, Ontario, Canada; 5Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Correspondence: A. Hillary Steinhart, Mount Sinai Hospital IBD Centre and University of Toronto, Toronto, ON, Canada, Room 445, 600 University Avenue, Toronto, Ontario M5G 1X5, e-mail hsteinhart@mtsinai.on.ca.

Abstract

Background: The efficacy of golimumab to induce and maintain remission in biologic-naïve patients with ulcerative colitis (UC) is established from placebo-controlled trials. However, golimumab’s real-world effectiveness, important to physicians and payers, remains unexplored.

Aim: The goal of this study was to describe real-world use and rate of persistence among UC patients with golimumab therapy and to assess factors that predict discontinuation during golimumab maintenance treatment.

Methods: A retrospective study of UC patients receiving golimumab maintenance therapy (August 2012–August 2015) was conducted on dosing data from a national case management program. Treatment persistence, defined as time from index prescription to the last dose (gap in dose >60 days), was assessed using Kaplan-Meier survival analysis. Predictors of treatment persistence were explored with Cox proportional hazards regression.

Results: One hundred thirty-six patients (50.7% male) with a mean (SD) age of 44.4 (15.6) years were included. At golimumab initiation, 72.1% were naïve to anti-TNFs; 77.2% received 200 mg, while 4.4% and 18.4% received 50 mg and 100 mg, respectively, every 4 weeks (induction therapy). The median time to discontinuation was 530 days, with a cumulative probability of 63% to remain on therapy at one year. Age, gender, golimumab induction, golimumab maintenance dose and prior anti-TNF exposure were not significantly associated with treatment persistence. Dose adjustment occurred in 7.4% of patients during maintenance treatment.

Conclusions: Overall, the persistence rate of golimumab observed in the current real-world study is similar to that described in previous single-centre UC cohorts and consistent with that seen in controlled clinical trials.

Keywords: Biologics; Compliance/adherence; Inflammatory bowel disease; Ulcerative colitis

The current guidelines for clinical management of ulcerative colitis (UC) recommend anti-TNF therapy for immunosuppressant-refractory, steroid-refractory or steroid-dependent patients (1–3). To date, three anti-TNF agents have been licensed for the treatment of UC: infliximab, adalimumab and golimumab. The efficacy of infliximab and adalimumab has been demonstrated in previous clinical trials (4–8). The efficacy of golimumab to induce and maintain remission in biologic-naïve patients with moderate to severe UC has been demonstrated in recently published, large, randomized controlled trials (5, 9–11). Although the efficacy of golimumab has been assessed in controlled settings and restricted patient populations...
(12), its effectiveness across diverse patient populations seen in routine clinical practice remains largely unexplored. This real-world effectiveness—important to patients, physicians and payers—can be efficiently and effectively be described using observational methods (13).

UC is characterized as a lifelong disease, with periods of quiescence. Increased persistence and a well-established measure of drug effectiveness encompassing factors such as drug tolerability, treatment compliance and clinical efficacy have been shown to improve the health benefits of approved treatments (14) and reduce health care expenditure (15, 16). To date, few single-centre studies have explored the rate of drug persistence with golimumab (17).

The current study aimed to examine the persistence with golimumab of UC patients within the nationwide case management program BioAdvance® and to explore patient factors associated with time to golimumab discontinuation.

MATERIALS AND METHODS

Study design and population

This was a retrospective analysis of data collected through a nationwide Canadian case management program (CMP; BioAdvance®) from August 2012 to August 2015 on golimumab-treated patients with UC. Data collection from physician and patient questionnaires includes patient demographics, prior biologic use and prescription data. Eligible patients for the analysis included adults (18–80 years) enrolled in the CMP that consented to have their data analyzed anonymously in aggregate, had a physician-confirmed diagnosis of UC and had received at least one dose of golimumab. Patients with incomplete data were excluded. A sample size of 130 patients would provide 80% power to detect a hazard ratio above 1.85 for a predictive factor (12). The main objective of the study was to provide an estimate of time to golimumab discontinuation.

Statistical analysis

The main objective of the study was to provide an estimate of discontinuation-free survival ( persistence) of golimumab for UC. Time to discontinuation, defined as the time from the index prescription to the last dose before a gap in dose >60 days, was assessed with the Kaplan-Meier survival method (right-censoring patients still on continuous treatment at their last assessment). The secondary objective was to assess factors that predict golimumab discontinuation during golimumab maintenance treatment. Both univariate- and multivariate-adjusted logistic regression analyses were used to assess potential risk factors, which included prior treatment with anti-TNF therapy, gender, age and golimumab induction and maintenance doses. Dose optimization was defined as any golimumab maintenance dose that differed (increased or decreased) from the first maintenance dose. Statistical analyses were carried out using SPSS 21.0 (SPSS Inc., Chicago, IL) and SAS 9.4 (SAS Institute, Cary, NC).

RESULTS

A total of 136 eligible patients were included in the analysis. The mean duration of follow-up was 188 days (median, 126 days). As of August 31, 2015, patients had been followed for a total of 70 patient-years.

Table 1 summarizes the patient population's baseline characteristics. The mean (SD) age was 44.4 (15.6) years, approximately half (50.7%) the patients were male, and the majority of patients (72.1%) were anti-TNF naive.

Based on survival analysis, patients persisted on golimumab for a median of 530 days, and the cumulative probability to remain on therapy after one year was 63% (Figure 1). Figures 2 and 3 describe persistence on golimumab by prior anti-TNF experience (P=0.71) and by gender (P=0.59), respectively, showing no significant association of either parameter with the outcome. In multivariate analysis, no statistical association between time to golimumab discontinuation and age (HR=1.01, P=0.34), gender (HR=1.20, P=0.59), golimumab induction dose (HR=1.33, P=0.46), golimumab maintenance dose (HR=1.56, P=0.99), or prior anti-TNF exposure (HR=1.14, P=0.71) was detected (Table 2).

Table 3 summarizes golimumab dose by prior biologic experience. The majority of patients (77.2%) received 200 mg of golimumab at induction, regardless of prior anti-TNF experience (naïve: 77.6%, experienced: 76.3%). Among anti-TNF-naïve patients, 71.6% of patients received a maintenance dose of 100 mg every four weeks. During the maintenance period, at a median time of 126.5 days, 10 (7.4%) patients underwent dose adjustment, corresponding to 8.2% of anti-TNF naïve patients and 5.3% of those previously treated with an anti-TNF.

Table 1. Overall patient and treatment characteristics

| Variable       | Level | Total |
|----------------|-------|-------|
| N=136          |       |       |
| Gender         |       |       |
| Female         | n (%) | 67 (49.3) |
| Male           | n (%) | 69 (50.7) |
| Age            | Mean (SD) | 44.4 (15.7) |
| Region*        |       |       |
| Western Canada | n (%) | 45 (33.1) |
| Maritimes      | n (%) | 13 (9.6) |
| Ontario        | n (%) | 44 (32.4) |
| Quebec         | n (%) | 34 (25.0) |
| Biologic Naive | n (%) | 38 (27.9) |
| No             | n (%) | 98 (72.1) |

*Maritimes includes these provinces: Nova Scotia and New Brunswick. Western Canada includes these provinces: Alberta, British Columbia, Manitoba and Saskatchewan.
Of these, seven patients had their golimumab dose increased, and three received a dose reduction.

**DISCUSSION**

The efficacy of golimumab in refractory moderate to severe UC has been shown in restricted populations of patients across several controlled clinical trials (7, 9, 11). In this study, we evaluated the persistence of golimumab therapy across a diverse patient population seen in routine clinical practice using dosing data from a comprehensive case management program. Persistence with therapy, defined as the amount of time that a patient remains on drug therapy, is an established surrogate measure of drug effectiveness in long-term observational and real-world studies, which incorporates several domains including drug tolerability, treatment compliance and clinical efficacy (18). Regarding the latter, previous studies have reported that persistence with anti-TNF therapy is associated with maintained clinical response (9, 11, 19). In the present study, 63% of patients remained on therapy after one year (median persistence of 530 days). In comparison, the clinical response rate at week 60 that was observed in the placebo-controlled, phase 3 PURSUIT trial, which included anti-TNF-naive patients only, was 50% (9, 11, 20). Thus, the outcomes appear similar—if not better—in this cohort, which includes TNF-naive and TNF-failure patients. This observation suggests that results of the PURSUIT randomized controlled trials could be generalized to the diverse patient populations seen in clinical practice.

To our knowledge, no prior studies have assessed persistence with golimumab treatment in UC patients in Canada. Furthermore, even though previous publications have reported data on persistence with anti-TNF agents, none have restricted the patient population to UC patients (21, 22), thus not allowing an indirect comparison with our study.

UC is a lifelong disease with an unpredictable pathogenesis marked by potentially long periods of inactivity. Uninterrupted maintenance treatment is recommended, even during periods of asymptomatic remission (14, 23). This is particularly important in chronic conditions where patients are at high risk for non-adherence (14, 24, 25). To date, this represents the first study aiming to identify significant predictors of discontinuation of golimumab maintenance treatment of UC. We did not identify significant predictive factors of golimumab persistence including, among others, previous biologic experience and gender. The study by Renna et al. evaluating the real-world effectiveness of golimumab and adalimumab identified no significant predictors of golimumab response and observed no differences between groups, based on previous biologic experience (anti-TNF naïve versus experienced) among patients who persisted on golimumab for eight weeks. However, these results should be compared to the present study findings with caution, due to the differing outcomes (response versus discontinuation) and follow-up periods (26).

Although to our knowledge no studies have directly evaluated persistence and potential predictive factors of golimumab
discontinuation in UC, similar studies have aimed to identify predictors of medication adherence (16, 23, 27–29). For instance, Lachaine et al. assessed medication adherence to any of the mesalamine-delayed/extended-release tablets using Canadian prescription claims. This study identified male gender (odds ratio [OR]=1.3; 95% confidence interval [CI], 1.1–1.6), older age (>60 years; OR=1.6; 95% CI, 1.3–2.0) and current use of corticosteroids (OR=1.4; 95% CI, 1.1–1.8) as predictors of high medication adherence (28). A study by Kane et al. assessing adherence with maintenance mesalamine in quiescent UC showed that males were twice as likely as females to be non-adherent with their UC treatment (24). However, our study did not assess medication adherence, but rather, persistence with golimumab treatment, which may explain the different findings. In rheumatoid arthritis, adherence to biologic therapies has been linked to lower health care resource utilization and the need for concomitant therapies such as corticosteroids (30). A study in rheumatoid arthritis (31) suggested that golimumab’s every four-week dosing schedule may account for some increased persistence compared to other subcutaneous therapies.

A minority of patients underwent dose adjustment (~7%) during a median follow-up time of 126.5 days. Our results concur with Detrez et al., who reported that adequate exposure to golimumab serum concentrations drives clinical response. Similar to our study, both study populations included anti-TNF-naïve and anti-TNF-experienced patients (17). Specifically, Detrez et al. reported 61.9% of patients maintaining a stable dose during follow-up without a significant difference between the anti-TNF-naïve and anti-TNF-experienced groups.

This study has several limitations. Persistence was used as a surrogate measure for efficacy (i.e., we assumed that a patient staying on golimumab is, in fact, continuing to have a response worthy of ongoing therapy). Due to the nature of the database, disease activity was not possible to be assessed. The fact that the majority of patients in this cohort were anti-TNF-naïve in an era where two other biologics are available for treatment of UC suggests that both the patient and treating physician felt ongoing use of golimumab was appropriate based on the clinical benefit. The assumption that patients who experience positive outcomes are more likely to persist treatment further solidifies this premise. Another limitation is that information on smoking and concomitant immunosuppressant use, which might influence drug persistence, was not available. While immunosuppressant use was not associated with golimumab response in the PURSUIT trial (9), combination therapy is generally thought to improve outcomes, especially in bio-naïve, immunosuppressant-naïve UC (33). Patient selection for treatment with golimumab was based on the judgement of the treating physicians, which may have resulted in selection bias; however, this is in line with the observational nature of the current study, and one would argue that the study population is reflective of

| Parameter                        | N   | Hazard Ratio | 95 % Confidence interval | P-value |
|----------------------------------|-----|--------------|--------------------------|---------|
| Anti-TNF naïve                   | 136 | 1.14         | 0.56–2.21                | 0.71    |
| Female gender                    | 136 | 1.20         | 0.63–2.27                | 0.59    |
| Age (years)                      | 136 | 1.01         | 0.99–1.03                | 0.34    |
| Induction dose (200 mg vs. 100 mg)| 136 | 1.33         | 0.63–2.83                | 0.46    |
| Maintenance dose (50 mg vs. 100 mg)| 136| 1.56         | 0.65–3.76                | 0.99    |

### Table 3. Golimumab dose by prior anti-TNF experience

| Variable                   | Level | Anti-TNF Naïve N=98 | Anti-TNF Experienced N=38 | Total N=136 |
|----------------------------|-------|---------------------|--------------------------|-------------|
| **Golimumab Induction**    |       |                     |                          |             |
| 50 mg                      | n (%) | 4 (4.1)             | 2 (5.3)                  | 6 (4.4)     |
| 100 mg                     | n (%) | 18 (18.4)           | 7 (18.4)                 | 25 (18.4)   |
| 200 mg                     | n (%) | 76 (77.6)           | 29 (76.3)                | 105 (77.2)  |
| **Golimumab Maintenance**  |       |                     |                          |             |
| 50 mg                      | n (%) | 16 (16.3)           | 5 (13.2)                 | 21 (15.4)   |
| 100 mg                     | n (%) | 53 (54.1)           | 30 (78.9)                | 83 (61.0)   |
| 200 mg                     | n (%) | 5 (5.1)             | 0 (0.0)                  | 5 (3.7)     |
| Missing                    | n (%) | 24 (24.5)           | 3 (7.9)                  | 27 (19.9)   |
| **Dose Adjustment**        |       |                     |                          |             |
| Unchanged                  | n (%) | 90 (91.8)           | 36 (94.7)                | 126 (92.6)  |
| Optimized                  | n (%) | 8 (8.2)             | 2 (5.3)                  | 10 (7.4)    |
the real-world. In addition, the database design, which is similar to claims data but with richer patient-level information, does not include some disease-related or patient-specific information such as biomarkers and concomitant medications that may be included in patient charts. Nonetheless, the present study design was selected due to statistical power afforded by such an approach, allowing us to examine the effectiveness of this product in a multi-centre real world setting. Furthermore, the study was powered to detect a hazard ratio above 1.75; therefore, any weaker effects would not be able to be detected as statistically significant in our study. Finally, time to golimumab discontinuation due to any reason was evaluated, and nonpersistence with golimumab could not be attributed to lack of efficacy or tolerability issues.

The major strength of the study is that it includes a large number of patients seen in real-world by both academic- and community-based gastroenterologists. This enhances the generalization of the findings to the UC population and broadens the possible use of golimumab into a TNF-exposed patient population.

In summary, the results of the current study have shown that the majority of patients persisted with golimumab therapy after one year, with a median of persistence of 530 days. A minority of patients underwent dose adjustment (~7%) during the follow-up period. These real-world data demonstrate the effectiveness of subcutaneous golimumab in the treatment of UC patients and suggest comparable or higher effectiveness compared with clinical trials across a broader patient population than those included in registration trials.

Acknowledgments
The authors wish to thank Ms. Clare Pollock and Dr. Angela Karellis for manuscript writing support. This work was supported by Janssen Inc. All authors have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted. BB made substantial contributions to study design, data interpretation and manuscript preparation. MW made substantial contributions to study design, data collection, data interpretation and manuscript preparation. BS made substantial contributions to study design, data collection, data interpretation and manuscript preparation. All authors approved the final submitted manuscript.

Conflicts of Interest
BB and AHS have served as consultants and have received honoraria and grants. MW and BS are employees of Janssen Inc. FC has served as a consultant of Janssen Inc. This study was funded in part by Janssen Inc. Writing support was provided by all authors, as well as Clare Pollock and Angela Karellis, both of JSS Medical Research Inc., and funded by Janssen Inc.

References
1. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management. J Crohns Colitis 2012;6(10):991–1030.
2. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105(3):501–23; quiz 524.
3. Bressler B, Marshall JK, Bernstein CN, et al.; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the management of nonhospitalized ulcerative colitis: The Toronto consensus. Gastroenterology 2015;148(5):1035–58. e1033.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
5. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142(2):257–65. e251–3.
6. Armuzzi A, Pugliese D, Danese S, et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2014;20(8):1368–74.
7. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 2011;60(6):780–7.
8. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008;2(3):219–25.
9. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146(1):96–109. e101.
10. Lowenberg M, de Boer N, Hoentjen F. Golimumab for the treatment of ulcerative colitis. Clin Exp Gastroenterol 2014;7:53–9.
11. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146(1):85–95; quiz e14-85.
12. Shealy DJ, Cai A, Staatker K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010;2(4):428–39.
13. Roche N, Reddel H, Martin R, et al. Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. Ann Am Thorac Soc 2014;11(Suppl 2):S99–104.
14. Kane SV. Systematic review: Adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23(5):577–85.

15. Hawthorne AB, Rubin G, Ghosh S. Review article: Medication non-adherence in ulcerative colitis—strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008;27(12):1157–66.

16. Kane S, Katz S, Jamal MM, et al. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflamm Bowel Dis 2012;18(8):1026–33.

17. Detrez I, Dreesen E, Van Stappen T, et al. Variability in golimumab exposure: A ‘Real-Life’ observational study in active ulcerative colitis. J Crohns Colitis 2016;10(5):575–81.

18. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995;9(4):619–32.

19. Castro-Laria L, Arguelles-Arias F, Garcia-Sanchez V, et al. Initial experience with golimumab in clinical practice for ulcerative colitis. Rev Esp Enferm Di 2016;108(3):129–32.

20. Rutgeerts P, Feagan BG, Marano CW, et al. Randomised clinical trial: A placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther 2015;42(5):504–14.

21. Degli Esposti L, Sangiorgi D, Perrone V, et al. Adherence and resource use among patients treated with biologic drugs: Findings from BEETLE study. Clinicoecon Outcomes Res 2014;6:401–7.

22. Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther 2012;29(8):664–74.

23. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007;102(7):1417–26.

24. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96(10):2929–33.

25. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003;114(1):39–43.

26. Renna S, Orlando E, Macaluso FS, et al. Letter: A prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. Aliment Pharmacol Ther 2016;44(3):310–1.

27. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003;1(3):170–3.

28. Lachaine J, Yen L, Beauchemin C, et al. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: Analyses with the RAMQ database. BMC Gastroenterol 2013;13:23.

29. Cerveny P, Bortlik M, Kubena A, et al. Nonadherence in inflammatory bowel disease: Results of factor analysis. Inflamm Bowel Dis 2007;13(10):1244–9.

30. Lathia U, Ewara EM, Nantel F. Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis. Patient Prefer Adherence 2017;11:1133–42.

31. Bhoi P, Bessette L, Bell M, et al. AB1040 comparison of adherence and dosing interval of subcutaneous anti-TNF biologics in inflammatory arthritis from A Canadian administrative database. Ann Rheum Dis 2016;75:1257–8.

32. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: Short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007;26(5):747–56.

33. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146(2):392–400.e393.